Bentley Cheatham

Bentley Cheatham is a seasoned executive with extensive experience in the biopharmaceutical industry. Currently serving as Vice President at Avolynt, Inc. since April 2016, Bentley previously held the position of CEO at BHV Pharma from 2013 to March 2016. Other notable roles include Vice President of R&D at Zen-Bio, Director of Biology at Ribonomics, and Director of Cell Therapy at Artecel Sciences. Academic contributions include serving as Assistant Professor at Harvard Medical School and Investigator at Joslin Diabetes Center. Bentley's educational background includes a PhD in Biochemistry from the University of Tennessee, Knoxville, and post-doctoral studies at Harvard Medical School.